Hutchison China MediTech Limited (HCM) Given Daily Media Sentiment Rating of 0.17

News articles about Hutchison China MediTech Limited (NASDAQ:HCM) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Hutchison China MediTech Limited earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.4847685315206 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several analysts recently commented on the stock. Canaccord Genuity set a $30.00 price target on shares of Hutchison China MediTech Limited and gave the company a “buy” rating in a research report on Thursday, May 18th. Zacks Investment Research downgraded shares of Hutchison China MediTech Limited from a “hold” rating to a “sell” rating in a research report on Monday, May 15th.

Shares of Hutchison China MediTech Limited (HCM) opened at 25.06 on Friday. Hutchison China MediTech Limited has a 52-week low of $10.61 and a 52-week high of $27.96.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-hutchison-china-meditech-limited-hcm-share-price-updated-updated.html.

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply